Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

  • This share is currently suspended. It was suspended at a price of 0.01
  • There is currently no data for VRS

Exercise of Options

7 Dec 2017 07:00

RNS Number : 6262Y
Versarien PLC
07 December 2017
 

7 December 2017

Versarien plc

("Versarien" or the "Company")

Exercise of Options

Director/PDMR Shareholding

Versarien plc (AIM: VRS), the advanced materials engineering group, announces it has issued 910,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares") following the exercise by directors and an employee of the Company under the Company's share option schemes.

Named person

No. options exercised

Exercise price per share

Neill Ricketts

250,000

12.25p

Chris Leigh

528,720

15.50p

Employee (non-PDMR)

132,180

12.25p

Total

910,900

 

 

Application has been made for the new Ordinary Shares to be admitted to trading on AIM, which is expected to take place on 11 December 2017. The new Ordinary Shares will rank, pari passu, with the existing Ordinary Shares in issue.

The Company was also notified that Christopher Leigh, Chief Financial Officer has sold 528,720 Ordinary Shares at an average price of 73.81 pence per Ordinary Share.

Following the transactions outlined above:

Mr Ricketts' interest in the share capital of the Company has increased to a total of 15,625,000 Ordinary Shares representing 10.53 per cent. of the Company's issued share capital enlarged pursuant to the exercise of options. Mr Ricketts is further interested in 278,720 options exercisable at 12.25 pence per share together with 2,626,614 options exercisable at 15 pence per share and 1,050,761 options exercisable at 29 pence per share; and

Mr Leigh's interest in the share capital of the Company has remained at a total of 315,000 Ordinary Shares representing 0.21 per cent. of the Company's issued share capital enlarged pursuant to the exercise of options. Mr Leigh is further interested in 2,626,614 options exercisable at 15 pence per share and 1,050,761 options exercisable at 29 pence per share.

Total Voting Rights

Following the issue of the new Ordinary Shares, the Company will have 148,386,309 ordinary shares of 1 pence each in issue. No Ordinary Shares are held in treasury. The figure of 148,386,309 may be used by the Company's shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

Versarien 01242 269 122

Neill Ricketts, CEO

Chris Leigh, CFO

WH Ireland (Nominated Advisor) 0117 945 3470

Mike Coe / Ed Allsopp

IFC Advisory (Financial PR and IR) 0203 053 8671

Tim Metcalfe

Graham Herring

Heather Armstrong

 

The information below, set out in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Neill Ricketts

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Versarien plc

b)

LEI

213800D6NZED7V8W2Z34

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1p each

 

GB00B8YZTJ80

b)

Nature of the transaction

Exercise of options

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

12.25p

250,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

250,000

£30,625

e)

Date of the transaction

5 December 2017

f)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christopher Leigh

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Versarien plc

b)

LEI

213800D6NZED7V8W2Z34

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1p each

 

GB00B8YZTJ80

b)

Nature of the transaction

Exercise and sale of options

c)

Price(s) and volume(s)

Exercise:

Price(s)

Volume(s)

15.50p

528,720

 

Sale:

Price(s)

Volume(s)

74.00p

73.64p

250,000

278,720

 

d)

Aggregated information

- Aggregated volume

- Price

 

- Aggregated volume

- Price

 Exercise:

528,720

£81,952

Sale:

528,720

£390,249

e)

Date of the transaction

5 December 2017

f)

Place of the transaction

London Stock Exchange, AIM

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKADPCBDDQBK
Date   Source Headline
9th Feb 20267:00 amRNSCancellation - Versarien Plc
6th Jan 20261:34 pmRNSAppointment of Administrators
19th Dec 20254:36 pmRNSUpdate on NOIA
19th Dec 20254:36 pmRNSUpdate on NOIA
15th Dec 20253:53 pmRNSUpdate on the Disposal of AAC Cyroma Limited
12th Dec 20257:00 amRNSUpdate on NOIA and Change of Registered Office
1st Dec 20257:30 amRNSSuspension - Versarien plc
1st Dec 20257:00 amRNSIntention to Appoint Administrators, Suspension
26th Nov 20257:00 amRNSUpdate - Proposed Disposal of the Company's Assets
31st Oct 20258:48 amRNSProposed Disposal of the Company’s Assets
29th Sep 20252:32 pmRNSCorporate Update
10th Sep 20251:00 pmRNSCorporate Update
29th Aug 20252:19 pmRNSCorporate Update
21st Aug 20257:00 amRNSStrategic Investment and Joint Venture Update
11th Aug 20257:00 amRNSCorporate Update
5th Aug 202511:03 amRNSHolding(s) in Company
29th Jul 20257:00 amRNSCorporate Update
22nd Jul 202510:55 amRNSSettlement of Legal Claims
4th Jul 20257:00 amRNS-RSouth American Polygrene™ Themoplastics Agreements
30th Jun 20253:03 pmRNSInterim Results
19th Jun 20252:34 pmRNSBuilding for Humanity – Contract Update
4th Jun 202511:49 amRNSHolding(s) in Company
2nd Jun 20252:03 pmRNSHolding(s) in Company
30th May 202510:19 amRNSHolding(s) in Company
30th May 20257:00 amRNSTotal Voting Rights
29th May 20253:29 pmRNSHolding(s) in Company
29th May 202510:20 amRNSHolding(s) in Company
27th May 202511:59 amRNSHolding(s) in Company
27th May 202511:02 amRNSHolding(s) in Company
23rd May 20259:38 amRNSHolding(s) in Company
22nd May 202511:56 amRNSHolding(s) in Company
21st May 202510:58 amRNSHolding(s) in Company
20th May 202511:11 amRNSHolding(s) in Company
14th May 20257:00 amRNSPlacing to raise £425,000
2nd May 202511:00 amRNSUpdate on Legal Claims
28th Apr 20251:04 pmRNSResult of AGM
27th Mar 20257:00 amRNSAudited Results for year ended 30 September 2024
24th Mar 202511:24 amRNSResult of General Meeting
10th Mar 20257:00 amRNS-RGraphinks™ supply agreement with Montana Química
5th Mar 20257:00 amRNSNotice of General Meeting
3rd Mar 20257:00 amRNSCompletion of Sale of Korean Assets
28th Feb 20257:00 amRNSTotal Voting Rights
27th Feb 20257:00 amRNSInnovate UK Loan Deed of Variation
10th Feb 20258:35 amRNSHolding(s) in Company
28th Jan 20252:36 pmRNSPlacing to raise £246k
30th Dec 202412:00 pmRNSUpdate on Sale of Korean Assets
13th Dec 20242:58 pmRNSHolding(s) in Company
13th Dec 202411:50 amRNSHolding(s) in Company
13th Dec 202410:11 amRNSHolding(s) in Company
13th Dec 20247:00 amRNS€804,000 Grant Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.